Report cover image

Global Lymphoma Treatment Drug Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 194 Pages
SKU # APRC20360181

Description

Summary

According to APO Research, the global Lymphoma Treatment Drug market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Lymphoma Treatment Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for Lymphoma Treatment Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Lymphoma Treatment Drug market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for Lymphoma Treatment Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Lymphoma Treatment Drug market include Johnson & Johnson, Roche, Abbvie, CHIPSCREEN and Celgene, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Lymphoma Treatment Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Lymphoma Treatment Drug, also provides the sales of main regions and countries. Of the upcoming market potential for Lymphoma Treatment Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Lymphoma Treatment Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Lymphoma Treatment Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Lymphoma Treatment Drug sales, projected growth trends, production technology, application and end-user industry.

Lymphoma Treatment Drug Segment by Company

Johnson & Johnson
Roche
Abbvie
CHIPSCREEN
Celgene
Lymphoma Treatment Drug Segment by Type

Oral
Injection
Lymphoma Treatment Drug Segment by Application

Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Lymphoma Treatment Drug Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global Lymphoma Treatment Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Lymphoma Treatment Drug market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Lymphoma Treatment Drug significant trends, drivers, influence factors in global and regions.
6. To analyze Lymphoma Treatment Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Lymphoma Treatment Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Lymphoma Treatment Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Lymphoma Treatment Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Lymphoma Treatment Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Lymphoma Treatment Drug industry.
Chapter 3: Detailed analysis of Lymphoma Treatment Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Lymphoma Treatment Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Lymphoma Treatment Drug in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Table of Contents

194 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Lymphoma Treatment Drug Sales Value (2020-2031)
1.2.2 Global Lymphoma Treatment Drug Sales Volume (2020-2031)
1.2.3 Global Lymphoma Treatment Drug Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 Lymphoma Treatment Drug Market Dynamics
2.1 Lymphoma Treatment Drug Industry Trends
2.2 Lymphoma Treatment Drug Industry Drivers
2.3 Lymphoma Treatment Drug Industry Opportunities and Challenges
2.4 Lymphoma Treatment Drug Industry Restraints
3 Lymphoma Treatment Drug Market by Company
3.1 Global Lymphoma Treatment Drug Company Revenue Ranking in 2024
3.2 Global Lymphoma Treatment Drug Revenue by Company (2020-2025)
3.3 Global Lymphoma Treatment Drug Sales Volume by Company (2020-2025)
3.4 Global Lymphoma Treatment Drug Average Price by Company (2020-2025)
3.5 Global Lymphoma Treatment Drug Company Ranking (2023-2025)
3.6 Global Lymphoma Treatment Drug Company Manufacturing Base and Headquarters
3.7 Global Lymphoma Treatment Drug Company Product Type and Application
3.8 Global Lymphoma Treatment Drug Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global Lymphoma Treatment Drug Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 Lymphoma Treatment Drug Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 Lymphoma Treatment Drug Market by Type
4.1 Lymphoma Treatment Drug Type Introduction
4.1.1 Oral
4.1.2 Injection
4.2 Global Lymphoma Treatment Drug Sales Volume by Type
4.2.1 Global Lymphoma Treatment Drug Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global Lymphoma Treatment Drug Sales Volume by Type (2020-2031)
4.2.3 Global Lymphoma Treatment Drug Sales Volume Share by Type (2020-2031)
4.3 Global Lymphoma Treatment Drug Sales Value by Type
4.3.1 Global Lymphoma Treatment Drug Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global Lymphoma Treatment Drug Sales Value by Type (2020-2031)
4.3.3 Global Lymphoma Treatment Drug Sales Value Share by Type (2020-2031)
5 Lymphoma Treatment Drug Market by Application
5.1 Lymphoma Treatment Drug Application Introduction
5.1.1 Hodgkin Lymphoma
5.1.2 Non-Hodgkin Lymphoma
5.2 Global Lymphoma Treatment Drug Sales Volume by Application
5.2.1 Global Lymphoma Treatment Drug Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global Lymphoma Treatment Drug Sales Volume by Application (2020-2031)
5.2.3 Global Lymphoma Treatment Drug Sales Volume Share by Application (2020-2031)
5.3 Global Lymphoma Treatment Drug Sales Value by Application
5.3.1 Global Lymphoma Treatment Drug Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global Lymphoma Treatment Drug Sales Value by Application (2020-2031)
5.3.3 Global Lymphoma Treatment Drug Sales Value Share by Application (2020-2031)
6 Lymphoma Treatment Drug Regional Sales and Value Analysis
6.1 Global Lymphoma Treatment Drug Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Lymphoma Treatment Drug Sales by Region (2020-2031)
6.2.1 Global Lymphoma Treatment Drug Sales by Region: 2020-2025
6.2.2 Global Lymphoma Treatment Drug Sales by Region (2026-2031)
6.3 Global Lymphoma Treatment Drug Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global Lymphoma Treatment Drug Sales Value by Region (2020-2031)
6.4.1 Global Lymphoma Treatment Drug Sales Value by Region: 2020-2025
6.4.2 Global Lymphoma Treatment Drug Sales Value by Region (2026-2031)
6.5 Global Lymphoma Treatment Drug Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America Lymphoma Treatment Drug Sales Value (2020-2031)
6.6.2 North America Lymphoma Treatment Drug Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe Lymphoma Treatment Drug Sales Value (2020-2031)
6.7.2 Europe Lymphoma Treatment Drug Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific Lymphoma Treatment Drug Sales Value (2020-2031)
6.8.2 Asia-Pacific Lymphoma Treatment Drug Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America Lymphoma Treatment Drug Sales Value (2020-2031)
6.9.2 South America Lymphoma Treatment Drug Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa Lymphoma Treatment Drug Sales Value (2020-2031)
6.10.2 Middle East & Africa Lymphoma Treatment Drug Sales Value Share by Country, 2024 VS 2031
7 Lymphoma Treatment Drug Country-level Sales and Value Analysis
7.1 Global Lymphoma Treatment Drug Sales by Country: 2020 VS 2024 VS 2031
7.2 Global Lymphoma Treatment Drug Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global Lymphoma Treatment Drug Sales by Country (2020-2031)
7.3.1 Global Lymphoma Treatment Drug Sales by Country (2020-2025)
7.3.2 Global Lymphoma Treatment Drug Sales by Country (2026-2031)
7.4 Global Lymphoma Treatment Drug Sales Value by Country (2020-2031)
7.4.1 Global Lymphoma Treatment Drug Sales Value by Country (2020-2025)
7.4.2 Global Lymphoma Treatment Drug Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA Lymphoma Treatment Drug Sales Value Growth Rate (2020-2031)
7.5.2 USA Lymphoma Treatment Drug Sales Value Share by Type, 2024 VS 2031
7.5.3 USA Lymphoma Treatment Drug Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada Lymphoma Treatment Drug Sales Value Growth Rate (2020-2031)
7.6.2 Canada Lymphoma Treatment Drug Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada Lymphoma Treatment Drug Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico Lymphoma Treatment Drug Sales Value Growth Rate (2020-2031)
7.6.2 Mexico Lymphoma Treatment Drug Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico Lymphoma Treatment Drug Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany Lymphoma Treatment Drug Sales Value Growth Rate (2020-2031)
7.8.2 Germany Lymphoma Treatment Drug Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany Lymphoma Treatment Drug Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France Lymphoma Treatment Drug Sales Value Growth Rate (2020-2031)
7.9.2 France Lymphoma Treatment Drug Sales Value Share by Type, 2024 VS 2031
7.9.3 France Lymphoma Treatment Drug Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. Lymphoma Treatment Drug Sales Value Growth Rate (2020-2031)
7.10.2 U.K. Lymphoma Treatment Drug Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. Lymphoma Treatment Drug Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy Lymphoma Treatment Drug Sales Value Growth Rate (2020-2031)
7.11.2 Italy Lymphoma Treatment Drug Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy Lymphoma Treatment Drug Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain Lymphoma Treatment Drug Sales Value Growth Rate (2020-2031)
7.12.2 Spain Lymphoma Treatment Drug Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain Lymphoma Treatment Drug Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia Lymphoma Treatment Drug Sales Value Growth Rate (2020-2031)
7.13.2 Russia Lymphoma Treatment Drug Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia Lymphoma Treatment Drug Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands Lymphoma Treatment Drug Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands Lymphoma Treatment Drug Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands Lymphoma Treatment Drug Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries Lymphoma Treatment Drug Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries Lymphoma Treatment Drug Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries Lymphoma Treatment Drug Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China Lymphoma Treatment Drug Sales Value Growth Rate (2020-2031)
7.16.2 China Lymphoma Treatment Drug Sales Value Share by Type, 2024 VS 2031
7.16.3 China Lymphoma Treatment Drug Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan Lymphoma Treatment Drug Sales Value Growth Rate (2020-2031)
7.17.2 Japan Lymphoma Treatment Drug Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan Lymphoma Treatment Drug Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea Lymphoma Treatment Drug Sales Value Growth Rate (2020-2031)
7.18.2 South Korea Lymphoma Treatment Drug Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea Lymphoma Treatment Drug Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India Lymphoma Treatment Drug Sales Value Growth Rate (2020-2031)
7.19.2 India Lymphoma Treatment Drug Sales Value Share by Type, 2024 VS 2031
7.19.3 India Lymphoma Treatment Drug Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia Lymphoma Treatment Drug Sales Value Growth Rate (2020-2031)
7.20.2 Australia Lymphoma Treatment Drug Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia Lymphoma Treatment Drug Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia Lymphoma Treatment Drug Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia Lymphoma Treatment Drug Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia Lymphoma Treatment Drug Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil Lymphoma Treatment Drug Sales Value Growth Rate (2020-2031)
7.22.2 Brazil Lymphoma Treatment Drug Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil Lymphoma Treatment Drug Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina Lymphoma Treatment Drug Sales Value Growth Rate (2020-2031)
7.23.2 Argentina Lymphoma Treatment Drug Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina Lymphoma Treatment Drug Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile Lymphoma Treatment Drug Sales Value Growth Rate (2020-2031)
7.24.2 Chile Lymphoma Treatment Drug Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile Lymphoma Treatment Drug Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia Lymphoma Treatment Drug Sales Value Growth Rate (2020-2031)
7.25.2 Colombia Lymphoma Treatment Drug Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia Lymphoma Treatment Drug Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru Lymphoma Treatment Drug Sales Value Growth Rate (2020-2031)
7.26.2 Peru Lymphoma Treatment Drug Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru Lymphoma Treatment Drug Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia Lymphoma Treatment Drug Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia Lymphoma Treatment Drug Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia Lymphoma Treatment Drug Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel Lymphoma Treatment Drug Sales Value Growth Rate (2020-2031)
7.28.2 Israel Lymphoma Treatment Drug Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel Lymphoma Treatment Drug Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE Lymphoma Treatment Drug Sales Value Growth Rate (2020-2031)
7.29.2 UAE Lymphoma Treatment Drug Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE Lymphoma Treatment Drug Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey Lymphoma Treatment Drug Sales Value Growth Rate (2020-2031)
7.30.2 Turkey Lymphoma Treatment Drug Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey Lymphoma Treatment Drug Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran Lymphoma Treatment Drug Sales Value Growth Rate (2020-2031)
7.31.2 Iran Lymphoma Treatment Drug Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran Lymphoma Treatment Drug Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt Lymphoma Treatment Drug Sales Value Growth Rate (2020-2031)
7.32.2 Egypt Lymphoma Treatment Drug Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt Lymphoma Treatment Drug Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Johnson & Johnson
8.1.1 Johnson & Johnson Comapny Information
8.1.2 Johnson & Johnson Business Overview
8.1.3 Johnson & Johnson Lymphoma Treatment Drug Sales, Value and Gross Margin (2020-2025)
8.1.4 Johnson & Johnson Lymphoma Treatment Drug Product Portfolio
8.1.5 Johnson & Johnson Recent Developments
8.2 Roche
8.2.1 Roche Comapny Information
8.2.2 Roche Business Overview
8.2.3 Roche Lymphoma Treatment Drug Sales, Value and Gross Margin (2020-2025)
8.2.4 Roche Lymphoma Treatment Drug Product Portfolio
8.2.5 Roche Recent Developments
8.3 Abbvie
8.3.1 Abbvie Comapny Information
8.3.2 Abbvie Business Overview
8.3.3 Abbvie Lymphoma Treatment Drug Sales, Value and Gross Margin (2020-2025)
8.3.4 Abbvie Lymphoma Treatment Drug Product Portfolio
8.3.5 Abbvie Recent Developments
8.4 CHIPSCREEN
8.4.1 CHIPSCREEN Comapny Information
8.4.2 CHIPSCREEN Business Overview
8.4.3 CHIPSCREEN Lymphoma Treatment Drug Sales, Value and Gross Margin (2020-2025)
8.4.4 CHIPSCREEN Lymphoma Treatment Drug Product Portfolio
8.4.5 CHIPSCREEN Recent Developments
8.5 Celgene
8.5.1 Celgene Comapny Information
8.5.2 Celgene Business Overview
8.5.3 Celgene Lymphoma Treatment Drug Sales, Value and Gross Margin (2020-2025)
8.5.4 Celgene Lymphoma Treatment Drug Product Portfolio
8.5.5 Celgene Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Lymphoma Treatment Drug Value Chain Analysis
9.1.1 Lymphoma Treatment Drug Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Lymphoma Treatment Drug Sales Mode & Process
9.2 Lymphoma Treatment Drug Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Lymphoma Treatment Drug Distributors
9.2.3 Lymphoma Treatment Drug Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.